Drug intelligence / Profile preview

LUNAR-HBV

Development stage: Preclinical
Lead developer: Arcturus Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

LUNAR-HBV is a combination RNA therapeutic developed for the treatment of chronic hepatitis B virus (HBV) infection. It comprises a combination of three UNA (Unlocked Nucleomonomer Agent) oligomers, designed to target all HBV transcripts and cover all major viral genotypes[1][9][10]. These UNA oligomers act as small interfering RNAs (siRNAs), delivered via the LUNAR nanoparticle platform, a novel biodegradable lipid-enabled delivery system[1][10]. This approach inhibits HBV gene expression by RNA interference, aiming to suppress viral replication and reduce HBV antigens, with the potential to minimize viral resistance by targeting multiple viral sequences[1][10]. The technology was developed by Arcturus Therapeutics, in collaboration with Janssen Pharmaceuticals[1][10].

Brand names: LUNAR-HBV
Other names: LUNAR-HBV

Targets

HBV RNA (Hepatitis B virus RNA)

Beyond the preview

Go deeper on LUNAR-HBV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LUNAR-HBV.

Explore the full profile